Opendata, web and dolomites

MetD-AO SIGNED

Methyl Donating artificial organelles to support liver cells in Non-alcoholic fatty liver disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetD-AO project word cloud

Explore the words cloud of the MetD-AO project. It provides you a very rough idea of what is the project "MetD-AO" about.

consisting    intracellular    deficiencies    missing    assemble    sized    gaining    assembly    synthetase    respectively    perform    prospects    outcome    carrier    adenosylmethionine    successful    single    protein    polymer    aos    release    nano    conduction    entirely    cellular    lost    ao    homeostasis    damage    organelles    escape    destroyed    trained    biosynthesis    encapsulated    host    acrylate    vitro    nanoparticles    mimicking    failing    methyl    donating    liver    reported    started    colloidal    oxygen    few    cell    carboxypentyl    biocatalytic    tail    organic    intact    substitute    self    cholesterol    disease    lysosome    expertise    nafld    cargo    poly    membranolytic    copolymers    biology    enzyme    complementary    amphiphilic    nonalcoholic    hepatocytes    spectrum    function    functional    chemist    science    stadler    methacrylate    employing    world    multiple    latter    characterization    fatty    encompassing    me    preserving    reactors    cytosol    pharmaceutical    chronic    dr    reactive    compartment    hydrophilic    lysosomal    prior    career    metd    reaction    artificial    synth    structurally    medical    western    therapeutic   

Project "MetD-AO" data sheet

The following table provides information about the project.

Coordinator
AARHUS UNIVERSITET 

Organization address
address: NORDRE RINGGADE 1
city: AARHUS C
postcode: 8000
website: www.au.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 219˙312 €
 EC max contribution 219˙312 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AARHUS UNIVERSITET DK (AARHUS C) coordinator 219˙312.00

Map

 Project objective

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world, encompassing a spectrum of liver damage. Multiple issues are involved on the cellular level in failing liver often including enzyme deficiencies such as reduced biosynthesis of S-adenosylmethionine (SAMe). Preserving SAMe homeostasis has only recently started to be considered as a potential therapeutic target in liver-related medical conditions. However, employing the required enzyme, SAMe synthetase (SAMe-synth), as a pharmaceutical, is challenging due to the general issues involved in intact (functional) protein delivery. The aim of the MetD-AO project is to assemble organic SAMe-synth activity mimicking polymer nanoparticles as artificial organelles (AO) and their in vitro characterization of intracellular function in hepatocytes. AOs are typically nano-sized single compartment reactors, aimed to perform a specific encapsulated biocatalytic reaction within a cell to substitute for missing or lost function. The AO will be based on amphiphilic copolymers consisting of a methyl-donating unit, cholesterol methacrylate and poly(5-carboxypentyl acrylate) as membranolytic hydrophilic tail. The latter two will aim at facilitating self-assembly and lysosomal escape, respectively. To allow structurally intact AO to escape the lysosome is unique since typically, the carrier is destroyed and only the therapeutic cargo is release into the cytosol. The proposed AOs with methyl-donating ability are highly advanced because the few prior reported AOs with intracellular activity all considered reactive oxygen related aspects at best. The successful outcome of MetD-AO has the potential to open up entirely new therapeutic opportunities in NAFLD. The complementary expertise of my host Dr. Stadler and me, a trained polymer chemist, will ensure a successful conduction of MetD-AO while it will enhance my future career prospects gaining experience in colloidal science and cell biology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METD-AO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METD-AO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MetEpiC (2020)

P53-dependent Metabolic and Epigenetic Reprogramming in Carcinogenesis

Read More  

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More  

ReproMech (2019)

The Molecular Mechanisms of Cell Fate Reprogramming in Vertebrate Eggs

Read More